The role of the transcriptional repressor ZEB2 in human neural crest cell formation and craniofacial pathology
- Institution
- STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY
- Principal investigator
- Rebekah Charney
- Funding
- $249K
- Duration
- 2024–2027
Moonbase score
Still being scored
Abstract
Project Summary The objective of this proposal is to delineate the role of the transcriptional repressor ZEB2 during human neural crest cell formation, craniofacial differentiation, and Mowat-Wilson Syndrome. The neural crest is a multipotent embryonic cell population unique to vertebrates which migrates extensively and differentiates into a variety of derivatives, including most of the craniofacial bone, cartilage, and dental organ tissues. Numerous human pathologies are associated with abnormal neural crest cell development, including the recently delineated neurocristopathy Mowat-Wilson Syndrome (MWS). MWS is a rare syndrome caused by de novo heterozygous mutations in ZEB2 leading to a distinct facial phenotype, dental abnormalities, intellectual disability, and other anomalies including Hirschprung disease which are indicative of neural crest cell defects at multiple axial levels. However, significant genotypic and phenotypic variability has been observed among MWS patients, and the underlying mechanisms that contribute to this disease are not well understood. Furthermore, while ZEB2 has been implicated as a major developmental regulator of the nervous system as well as in neural crest cell epithelial-to-mesenchymal transition and migration, recent evidence in our human neural crest cell model indicates a crucial role for ZEB2 in the early formation of the neural plate border and neural crest. ZEB2 is known to negatively regulate TGFb superfamily signaling, whose modulation is essential for proper neural crest formation and differentiation. Therefore, it is hypothesized that ZEB2 functions reiteratively to establish the repressive epigenetic landscape throughout neural crest cell formation and craniofacial development by modulating proper TGFb superfamily signaling, and that the failure of this regulation underscores the MWS pathology. To test this hypothesis, three specific aims are proposed. Aim 1 will examine the modular functionality of ZEB2 in regulating the proper levels of TGFb signaling throughout wild-type human cranial neural crest cell formation. In particular, the cis-regulatory interactions between ZEB2 and TGFb receptor activated Smad proteins and the functional requirement of co-repressors leading to changes in chromatin accessibility will be delineated. In Aim 2, the MWS pathology will be addressed through the establishment of induced pluripotent stem cells from MWS patients of diverse genotypes. Using these tools, the precise transcriptomic and epigenetic misregulation during MWS-based neural crest cell formation will be interrogated, providing much needed molecular insight into this understudied pathology. In Aim 3 of this proposal, the role of ZEB2 in wild-type and MWS human tooth formation will be interrogated through the establishment of a human neural crest cell-based tooth organoid model. These results will reveal for the first time the molecular role of this transcriptional repressor throughout multiple stages of human neural crest cell formation, differentiation, and pathology.
LOADING MOONBASE SCORE
Questions for STATE UNIVERSITY OF NEW YORK AT BUFFALO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · State University of New York at Buffalo48
Bacterial sialometabolic activity impacts periodontal immunity and microbiota
Ashu Sharma · $379K · 2020–2026
- NIH · State University of New York at Buffalo46
Model-aided Design and Integration of Functionalized Hybrid Nanomaterials for Enhanced Bioremediation of Per-and Polyfluoroalkyl Substances (PFASs)
Diana S Aga · $282K · 2021–2025
- NIH · State University of New York at Buffalo43
Role of cardiac clock misalignment in promoting arrhythmias in swine and donor human hearts
Kedar Kirtikumar Aras · $721K · 2025–2030